ITMCTR2000003304招募中4 期
A multicenter, randomized, double-blind, placebo-controlled trial for Lu-Dang-Shen oral liquid in the treatment of reduced digestion function of convalescent new coronavirus pneumonia (COVID-19) patient
Wuhan Third Hospital0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70（—）
- 性别
- All
入选标准
- •1. Meet the diagnostic criteria of the n Novel Coronavirus Pneumonia (COVID-19) in the recovery period;
- •2. Patients with fatigue, anorexia, abdominal distension, loose stools and other digestive dysfunction as the main clinical manifestations, 3 of them at the same time, or a single symptom visual analog score (VAS) greater than 5 points;
- •3. Heal patients who have been discharged for more than 2 weeks;
- •4. Aged 18-70 years old;
- •5. Sign the informed consent.
排除标准
- •1. Patients with fatigue, anorexia, abdominal distension, loose stools due to other reasons or diseases of the digestive system;
- •2. Patients with difficulties in taking oral drugs due to underlying diseases and other reasons;
- •3. It is accompanied by serious basic diseases that affect survival, including uncontrolled clinically meaningful heart, lung, kidney, digestion, blood disease, neuropsychiatric disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc ;
- •4. People with allergies and allergies to the drugs involved in the treatment plan;
- •5. Women during pregnancy or lactation;
- •6. Those who cannot cooperate with their mental state, those who suffer from mental illness, lack self-control, and cannot express clearly;
- •7. Those who are participating in other clinical trials;
- •8. According to the judgment of the investigator, there will be patients who are complicated to enroll or have poor compliance, etc., which affect the efficacy and safety evaluation.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutationsvascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutationsMedDRA version: 20.0Level: PTClassification code 10014316Term: Ehlers-Danlos syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006574-23-NLAytu BioPharma, Inc.260
进行中（未招募）
1 期
A clinical study to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent, after surgical treatment and/or Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrentMedDRA version: 21.1Level: LLTClassification code 10068739Term: Chronic thromboembolic pulmonary hypertensionSystem Organ Class: 100000004855EUCTR2018-002823-41-ATActelion Pharmaceuticals Ltd280
进行中（未招募）
1 期
EVOLVE-FD: Effects of EVOLocumab VErsus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids in patients with Familial DysbetalipoproteinemiaFamilial DysbetalipoproteinemiaEUCTR2018-003476-12-NLniversity Medical Center Utrecht30
进行中（未招募）
1 期
A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.Patients with genetically ascertained Unverricht-Lundborg disease (ULD).MedDRA version: 8.1Level: LLTClassification code 10054894Term: Unverricht-Lundborg diseaseEUCTR2006-000169-12-FRCB S.A.42
进行中（未招募）
1 期
Efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failureAcute heart failureEUCTR2013-001498-25-ATovartis Pharma Services AG6,800